Detalles de la búsqueda
1.
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 186(3): 466-475, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652810
2.
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
J Eur Acad Dermatol Venereol
; 36(12): 2393-2400, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920762
3.
Calculation of the Biological Efficiency of the Proton Component from 14.8 MeV Neutron Irradiation in Computational Biology with Help of Video Cards.
Bull Exp Biol Med
; 173(2): 281-285, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35737156
4.
Differential Markers of Subpopulations of Epithelial Cells of the Larynx in Squamous Cell Carcinoma.
Bull Exp Biol Med
; 173(4): 553-559, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094593
5.
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Br J Dermatol
; 185(6): 1146-1159, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34105767
6.
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Br J Dermatol
; 184(4): 652-662, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32652544
7.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Br J Dermatol
; 182(6): 1348-1358, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31887225
8.
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
J Eur Acad Dermatol Venereol
; 34(2): 301-309, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31479549
9.
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Br J Dermatol
; 178(1): 132-139, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28940259
10.
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Br J Dermatol
; 179(2): 320-328, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29488226
11.
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
J Eur Acad Dermatol Venereol
; 32(8): 1297-1304, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29524255
12.
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
J Eur Acad Dermatol Venereol
; 32(11): 1940-1949, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29706008
13.
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
J Eur Acad Dermatol Venereol
; 31(6): 1004-1013, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28190255
14.
Defining drug-free remission of skin disease in patients with plaque psoriasis.
Br J Dermatol
; 182(6): 1484-1487, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31705649
15.
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
J Eur Acad Dermatol Venereol
; 29(4): 767-76, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25284275
16.
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
Br J Dermatol
; 170(3): 705-15, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24079852
17.
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 169(6): 1337-41, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24032554
18.
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Br J Dermatol
; 179(4): 984-986, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29747219
19.
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
J Eur Acad Dermatol Venereol
; 27(10): 1252-61, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23157612
20.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
J Eur Acad Dermatol Venereol
; 27(12): 1535-45, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23279003